Dupixent Sales Growth in 2020
Dupixent (dupilumab), developed by Sanofi and Regeneron, saw sales rise in Q1, Q2, and Q4 of 2020 compared to the prior year. Global sales grew 83% in Q1 to €1.02 billion, 70% in Q2 to €1.14 billion, and 57% in Q4 to €1.42 billion. Q3 sales of €1.20 billion increased 38% year-over-year but at a slower pace than other quarters.[1]
Year-over-Year Quarterly Breakdown
| Quarter | 2020 Sales (€ billion) | YoY Growth |
|---------|-------------------------|------------|
| Q1 | 1.02 | +83% |
| Q2 | 1.14 | +70% |
| Q3 | 1.20 | +38% |
| Q4 | 1.42 | +57% |
Full-year sales reached €4.78 billion, up 63%.[1]
Why Sales Surged That Year
Growth stemmed from expanded U.S. approvals for asthma and chronic rhinosinusitis with nasal polyps, plus strong atopic dermatitis demand. COVID-19 lockdowns briefly slowed new patient starts in Q2 but rebounded quickly.[1][2]
U.S. vs. Rest of World Performance
U.S. sales, driving most growth, hit $2.6 billion for the year (+92% YoY), with quarterly gains across all periods. International sales added €2.18 billion (+27%).[1]
How Growth Compares to 2019 and 2021
In 2019, quarterly sales hovered around €600-700 million. 2021 accelerated to €6.8 billion total (+42%). Dupixent's trajectory outpaced many biologics amid rising allergy/immunology needs.[1][2]
[1]: Sanofi 2020 Full Year Results
[2]: Regeneron 2020 Q4 Earnings